Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Gemtuzumab ozogamicin (compound)


DrugBank
Identification
Name: gemtuzumab ozogamicin
Name (isomeric): DB00056
Drug Type: biotech
Synonyms:
anti-CD33; Mylotarg
Brand: Mylotarg (Wyeth), Mylotarg
Category: Antineoplastic Agents
CAS number: 220578-59-6
Pharmacology
Indication: For treatment of CD33-positive acute myeloid leukemia in patients 60 and over who are not candidates for other chemotherapy.
Pharmacology:
Used for the treatment of acute myeloid leukemia (AML), mylotarg binds to the CD33 antigen, which is expressed on the surface of leukemic cells in more than 80% of patients with AML. The CD33 antigen is not expressed on pluripotent hematopoietic stem cells or nonhematopoietic cells. This gives mylotarg the selectivity needed to target leukemic cell...
show more »
Mechanism of Action:
Mylotarg is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin de...
show more »
Biotransformation: Most likely removed by opsonization via the reticuloendothelial system.
Toxicity: The most frequently reported toxicities are myelosuppression and hepatic veno-occlusive disorder.
Affected organisms: Humans and other mammals

Targets